STERIS plc (STE) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with increased net income, free cash flow, and dividends. Despite tariff challenges, the company maintains growth expectations and reports strong order growth across segments. The Q&A reveals confidence in market positions and future prospects, with no major concerns raised by analysts. The positive sentiment is supported by organic revenue growth, margin improvements, and strategic cash management plans, suggesting a likely stock price increase in the short term.
Key Financial Performance
Total as reported revenue Grew 9% year-over-year. Constant currency organic revenue grew 8%, driven by volume and 230 basis points of price.
Gross margin Increased 20 basis points year-over-year to 45.3%. Positive price and productivity outpaced inflation and tariff costs.
EBIT margin Increased 50 basis points year-over-year to 22.8% of revenue, due to improvement in gross margin and operating expense leverage.
Adjusted effective tax rate Increased to 23.5% year-over-year, driven primarily by geographic mix and changes in discrete item adjustments.
Net income from continuing operations $231.2 million, with adjusted earnings per diluted share from continuing operations at $2.34, a 15% improvement year-over-year.
Capital expenditures $94 million for the first quarter of fiscal 2026.
Depreciation and amortization $119 million for the first quarter of fiscal 2026.
Total debt $1.9 billion at the end of the quarter, with gross debt to EBITDA at 1.2x.
Free cash flow $327 million for the first quarter of fiscal 2026, driven by an increase in earnings and improvements in working capital.
Dividend Increased by 10% to $0.63 per quarter, marking the 20th consecutive year of dividend increases.
Healthcare constant currency organic revenue Grew 8% year-over-year, with capital equipment revenue up 6%, service revenue up 13%, and consumables revenue up 5%. EBIT margins increased 10 basis points to 24.2%, offsetting tariffs and inflation.
AST constant currency organic revenue Grew 10% year-over-year, with services revenue up 12%. EBIT margins increased 150 basis points to 48.6%, offsetting increases in energy and labor costs.
Life Sciences constant currency organic revenue Increased 4% year-over-year, with consumables revenue up 8%, services revenue up 3%, and capital equipment revenue flat. Margins increased 260 basis points due to favorable mix, pricing, and productivity.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Healthcare Segment Growth: Constant currency organic revenue grew 8% in Q1, with growth across all categories. Healthcare capital equipment revenue increased 6%, with underlying order growth of 14% and backlog over $400 million. Service revenue grew 13%, and Consumables grew 5%.
AST Segment Growth: Constant currency organic revenue grew 10% in Q1, with 12% growth in Services. Services benefited from currency, bioprocessing demand, and stable medical device volumes.
Life Sciences Segment Growth: Constant currency organic revenue increased 4% in Q1, driven by 8% growth in Consumables and 3% growth in Services. Capital equipment revenue was flat, but backlog increased over 50% to $111 million.
Revenue Growth: Total as-reported revenue grew 9% in Q1, with constant currency organic revenue up 8%, driven by volume and pricing.
Margin Improvements: Gross margin increased 20 basis points to 45.3%, and EBIT margin increased 50 basis points to 22.8% due to improved gross margin and operating expense leverage.
Free Cash Flow: Free cash flow for Q1 was $327 million, driven by increased earnings and working capital improvements.
Debt Reduction: Total debt reduced to $1.9 billion, with gross debt to EBITDA at 1.2x.
CFO Transition: Long-serving CFO Michael Tokich announced his transition, with Karen (a long-time team member) set to take over. Michael will remain as a special financial adviser to ensure a smooth transition.
Dividend Increase: The company announced its 20th consecutive year of dividend increases, with a 10% rise to $0.63 per quarter.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Costs: The company faces $45 million in tariff costs for fiscal 2026, an increase of $15 million from the previous quarter. This could impact profitability, particularly in the Healthcare segment.
Energy and Labor Costs: Increases in energy and labor costs are noted, particularly affecting the AST segment. These rising costs could pressure margins if not offset by pricing and volume growth.
Currency Fluctuations: Significant shifts in forward currency rates have led to adjustments in revenue outlook. While favorable currency offsets some costs, ongoing volatility could pose risks to financial performance.
Healthcare Segment Tariffs and Inflation: The Healthcare segment is impacted by tariffs and inflation, which are partially offset by pricing and productivity improvements. Persistent inflationary pressures could challenge margin expansion.
Capital Equipment Revenue in Life Sciences: Capital equipment revenue in the Life Sciences group was flat, despite a 50% increase in backlog. This stagnation could indicate challenges in converting backlog to revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: STERIS anticipates approximately 8% to 9% revenue growth for fiscal 2026, reflecting about 200 basis points of favorable currency. Constant currency organic revenue growth is expected to remain at 6% to 7%.
Segment Growth: Each segment is expected to grow constant currency organic revenue in the range of 6% to 7% for fiscal 2026. AST's revenue and growth in the first quarter were stronger than anticipated, but the outlook for the year remains unchanged.
Earnings Outlook: The earnings outlook for fiscal 2026 is unchanged at $9.90 to $10.15 per diluted share, reflecting $45 million in tariff costs, an increase of $15 million over the previous quarter. Favorable foreign currency is expected to offset this increase.
Free Cash Flow: The outlook for free cash flow has been increased by $50 million to $820 million for fiscal 2026.
Capital Expenditures: CapEx remains unchanged at $375 million for fiscal 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Increase: Last week, we announced our 20th consecutive year of dividend increases with a 10% increase to $0.63 per quarter as we continue to prioritize consistent dividend growth.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What drove the increased tariff estimate?
A:The increase was driven by additional tariffs on metals: steel and aluminum tariffs increased from 25% to 50%, copper went from 0% to 50%, and the EU changed from 10% to 15%. These changes occurred after the mid-May guidance.
Q:Why is the company maintaining a 6%-7% organic growth expectation for AST despite a strong start?
A:The company is maintaining this range due to general conservatism and some moving parts in MedTech, including changes in manufacturing positions by customers. They remain confident in their numbers but acknowledge potential variability.
Q:What is the update on the bioprocessing market?
A:The bioprocessing market has shown consistent volumes over the last 4-5 months, returning to a normal trajectory after a reset base. The company assumes customers are not overbuilding inventory.
Q:What is driving the strong increase in the Life Science segment's backlog?
A:The increase is driven by the completion of a down cycle in capital orders caused by customer layoffs, plant relocations, and a slowdown in vaccines. The company has seen strong order intake and feels positive about catching up in this space.
Q:What is the company's perspective on competitor comments about procedure softness and purchasing delays?
A:The company has not observed any slowdown in volumes or backlog growth. They feel confident in their position and are unsure of the basis for the competitor's comments.
Q:What is causing the higher employee healthcare benefit costs?
A:The increase is due to higher utilization of employee healthcare benefits, despite only low single-digit premium increases.
Q:What is driving the strong order growth in Healthcare and Life Sciences?
A:Strong order growth is attributed to a robust portfolio and strong partnerships with large customers. The backlog supports confidence in the full-year revenue guide.
Q:What is the company's plan for its cash balance?
A:The company plans to continue building its cash position due to limited prepayable debt. They will also continue buybacks to offset dilution and remain active in M&A opportunities.
Q:How does the company view the regulatory relief for ethylene oxide sterilization facilities?
A:The company did not apply for the relief as their facilities are already compliant. They believe the relief may extend the timeline for some competitors but is not materially significant.
Q:What is the company's outlook on hospital volumes and the impact of OB3?
A:The company sees OB3 as a payment reimbursement issue for hospitals rather than a demand issue. They have not observed any pullback in procedure volumes or orders.
Q:How does FX impact the company's profitability?
A:The company is largely operationally hedged on FX. While FX increases the top line, it is offset by incremental tariffs, resulting in minimal impact on profitability.
Q:What is the company's perspective on the ASC build-out in the U.S.?
A:The company views the ASC build-out as beneficial for its capital business. They aim to address unmet demands by providing training and compliance programs for these facilities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the potential impact of OB3 on hospital volumes, stating it is more of a payment reimbursement issue. Additionally, they did not provide clarity on the timeline or specifics of larger M&A opportunities, stating they are hard to predict.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AST basis
AST start
Adam Fishbin
Bednar Piper
Brett Adam
CEO Director
CFO Brett
CFO acumen
CFO aspect
CFO position
CFO term
CFO transition
Capital Markets
Co Research
Communications Tokich
Conference Instructions
Consumables Healthcare
Corporate Communications
Director Winter
Division Conference
Division Howard
Division Jason
Division McLaurin
Division Polark
Inc Research
LLC Research
Research Division
Services
change
dividend
improvement
moment
point volume
pricing productivity
start outlook
tariff
volume pricing
STE Transcript
STERIS plc (STE) Q4 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights strong financial performance with expanded EBIT margins and double-digit EPS growth. The Q&A session reveals operational improvements and strategic moves like the $1 billion buyback and tuck-in M&A, suggesting future growth. Despite some challenges, such as tough comps and weather impacts, management's optimistic guidance and strategic investments in high-margin areas indicate a positive outlook. The sentiment is further bolstered by the commitment to shareholder returns and operational efficiencies, supporting a positive stock price movement prediction.
STERIS plc (STE) Q3 2026 Earnings Call Transcript
Positive2-5
The earnings call reveals solid financial performance, with increased revenue and improved EBIT margins in key segments. Despite some margin declines due to tariffs, the overall outlook remains optimistic, supported by strong growth in Life Sciences and AST. The Q&A section highlights effective mitigation strategies for tariffs and positive market trends, such as capacity expansions. The increase in earnings and free cash flow guidance further supports a positive sentiment. However, the lack of major M&A and conservative cash flow guidance slightly temper the outlook, leading to a positive but not strong positive prediction.
STERIS plc (STE) Q2 2026 Earnings Call Transcript
Positive11-6
The earnings call reflects strong financial performance with a 15% increase in EPS and robust free cash flow. The company anticipates 8-9% revenue growth and maintains strong growth across segments. Positive factors include increased EBIT margins and solid growth in healthcare and AST services. Despite headwinds from tariffs and inflation, the guidance remains optimistic, supported by strategic expansions and stable demand. The Q&A session reinforced management's confidence in sustained growth, though some responses lacked detail. Given these factors, a positive stock price movement is expected.
STERIS plc (STE) Q1 2026 Earnings Call Transcript
Positive8-7
The earnings call indicates strong financial performance with increased net income, free cash flow, and dividends. Despite tariff challenges, the company maintains growth expectations and reports strong order growth across segments. The Q&A reveals confidence in market positions and future prospects, with no major concerns raised by analysts. The positive sentiment is supported by organic revenue growth, margin improvements, and strategic cash management plans, suggesting a likely stock price increase in the short term.
STE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
